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The activity of mefloquine (Mef) and related compounds on previously characterized 
Streptococcus pneumoniae strains carrying defined amino acid substitutions in the c 
subunit of the F0F1 H+-ATPase was studied. In addition, a series of MefR strains were 
isolated and characterized. A good correlation was observed between inhibition of 
growth and inhibition of the membrane-associated F0F1 H+-ATPase activity. Mef was 
about 10-fold more active than optochin and about 200-fold more active than quinine in 
inhibiting both growth and ATPase activities of the laboratory pneumococcal strain R6. 
Mutant strains showed different degrees of inhibition by the different compounds, 
depending on their specific mutations at the c subunit. The resistant strains studied here 
had point mutations that change amino acid residues either in the c or a subunits of the 
F0 complex. Changes in the c subunit were located in one of the two transmembrane -
helices: residues M13, G14, G20, M23 and N24 of helix-1; residues M44, G47, V48, A49 
and V57 of helix-2. Changes at the a subunit were also found in either of the 
transmembrane -helices 5 or 6: residue L186 of helix 5; residues W206, F209, and S214 
of helix 6. These results suggest that the transmembrane helices of the c and a subunits 
interact and that the mutated residues are important for the structure of the F0 complex 
and proton translocation.   
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 The prevalence of Streptococcus pneumoniae strains resistant to common 
antimicrobial agents (10, 26), and the emergence of resistance to new drugs, as the 
fluoroquinolones (4, 20), has highlighted the need for novel antimicrobial agents directed at 
new targets. The membrane-associated F0F1 H
+
-ATPase could be such a target, given that the 
unique sensitivity of S. pneumoniae to the amino alcohol antimalarial agents optochin (Opt) 
and quinine (Qin) resides in the characteristics of its F0 complex (6, 24). The H
+-ATPase 
could be essential for the viability of the pneumococcus, as demonstrated in Lactococcus 
lactis, a genetically related species (17). The primary role of this enzyme in S. pneumoniae is 
to create a proton gradient with the energy provided by ATP hydrolysis, and to maintain the 
intracellular pH via proton extrusion (21) as in other related bacteria (7, 14). However, in 
bacteria with a respiratory chain such as Escherichia coli, the primary role of this enzyme is to 
synthesize ATP from the proton gradient of the respiratory chain. The bacterial F0F1 ATPases 
consist in a cytoplasmic sector F1 (, , , , and  subunits), which contains the catalytic sites 
for ATP hydrolysis, and a cytoplasmic membrane sector F0 (a, c, and b subunits), which forms 
the proton channel. Proton transport through F0 drives the release of ATP on F1 by long-range 
conformational changes. The protonation state of an acidic residue of the c subunit produces 
conformational changes that drive the rotation of an oligomeric ring of these subunits. This 
rotation, in turn, causes the rotation of the attached  and  subunits, producing 
conformational changes in the  subunits (28, 33) that result in ATP synthesis (1). 
Conversely, hydrolysis of ATP in F1 generates rotation of  and , resulting in the pumping of 
protons back across the membrane through F0. In S. pneumoniae (21), as well as in other 
related bacteria (2, 15-18) an increase in the activity of the F0F1 ATPase as the pH of the 
growth medium decreases has been observed. The regulation of this pH-inducible phenotype 
occurs in S. pneumoniae at the level of initiation of transcription (21).  
Although Opt was used at the beginning of the 20th century for the treatment of 
pneumococcal infections (23), its use is nowadays restricted to diagnostic purposes due to its 
high toxicity. However, new related, less toxic compounds have been synthesized (19). Given 
the special characteristics of the pneumococcal F0F1 ATPase, and its role in the maintenance 
of intracellular pH, this enzyme could be considered to be a target for the design of new 
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antibacterial agents. Moreover, the pneumococcus could be also considered as a model system 
for the study of the putative antimalarial activity of new compounds (24). 
In the present study, we describe the molecular basis of the antipneumococcal 
behaviour of mefloquine (Mef) and related compounds. The activity of these compounds on 
the growth and membrane-associated ATPase activity on S. pneumoniae strains with defined 
mutations in the c and a subunits of the F0 complex of the F0F1 ATPase has been studied. In 
addition, Mef-resistant (MefR) strains have been isolated and characterized. 
 
MATERIALS AND METHODS 
 Bacterial strains, growth and transformation of bacteria. The strains of S. pneumoniae 
used were: the common laboratory strain R6, the Opt- and Qin-resistant R6 derivatives MJ11, 
MJ2 (6), MJQ3, and MJQ4 (24), and strains ATCC 6303 and ATCC 49619 that were employed 
as quality controls for antimalarials (18). Unless otherwise stated, strain R6 was grown in liquid 
C medium, containing 0.08% yeast extract and transformation was carried out according to 
Tomasz (34). Cultures containing 9 × 106 CFU per ml were treated with DNA at 0.1 g/ml for 
40 min at 30 ºC, then at 37 ºC for 90 min, before plating on media plates containing 0.3 g/ml 
Mef.  
 Susceptibility tests. MICs were determined by the microdilution method, using cation-
adjusted Mueller-Hinton broth supplemented with 2.5% lysed horse blood as recommended 
by the National Committee for Clinical Laboratory Standards (25). The inoculum was 
prepared by suspension of several colonies from an overnight blood agar culture in Mueller-
Hinton broth and adjusting the turbidity to the 0.5 McFarland standard (ca. 108 CFU/ml). The 
suspension was further diluted to provide a final bacterial concentration of 105 CFU/ml in 
each well of the microdilution trays. Plates were covered with plastic tapes and incubated in 
ambient atmosphere at 37ºC for 20-24 h. MIC was defined as the lowest concentration of drug 
that inhibited visible growth. S. pneumoniae ATCC strains 49619 and 6303 were used for the 
quality control.    
 PCR amplification and DNA sequence determination. S. pneumoniae chromosomal 
DNA was obtained as described previously (6). PCR amplifications were performed using 1 
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unit of Thermus thermophilus thermostable DNA polymerase (Biotools), 1 g of 
chromosomal DNA, 0.4 M (each) of the synthetic oligonucleotide primers, 0.2 mM of each 
dNTP, and 2 mM MgCl2 in a final volume of 50 l. To amplify the atpC and atpA genes, 
oligonucleotides atporf1 (5’-ggtcggaaTTCTGGATGGCTAACTTGAACTTG-3’), 
corresponding to nucleotides –143 to –120 upstream of atpC, and atpB56 (5’-
GACGGGCTTCTTCAGCTCTGTC-3’) (the complementary strand of the primer coding for 
DRAEEAR of subunit b), were used. The 5’ end of atporf1 contained a sequence including an 
EcoRI restriction site, which is shown underlined. Amplification was achieved with an initial 
cycle of 1 min denaturation at 94ºC, and 30 cycles of 30 seconds at 94ºC, 90 seconds at 55ºC 
and 75 seconds polymerase extension step at 72ºC, with a final 8 min 72ºC extension step and 
slow cooling at 4ºC. PCR products used in control experiments of transformation were 
obtained with 2,6 units of a proof-reading enzyme, Expand High Fidelity PCR system 
(Boehringer Manheim). The parE fragment used in these experiments was amplified with 
oligonucleotides parE105 (5’-GGAGGGAAATTCGGTCAAGGTGGCTA-3’) (coding for 
GGKFGNGGY) and parE483 (9). Gel electrophoresis of PCR products was carried out in 
agarose gels as described (32). DNA fragments were purified using MicroSpinTM S400 HR 
columns (Amersham Pharmacia Biotech) and were sequenced on both strands with an 
Applied Biosystems Prism 377 DNA sequencer, accordingly to protocols provided by the 
manufacturer with both the primers used for the PCR amplifications and internal primers. 
 ATPase activity determinations. Membrane-associated ATPase activity was measured 
as described (24). One unit of activity was defined as the amount of enzyme that resulted in 
the release of 1 mol of inorganic phosphate (Pi) per ml per 30 min. IC50 values (mean of two 
independent determinations) were defined as the concentration of the antimalarial agent 
required for a 50% reduction of enzymatic activity. 
 Chemicals. Opt and Qin were purchased from Sigma Chemical., St. Louis, Mo. Mef (Ro 
21-5998-000) was provided by Roche Laboratories, Basel, Switzerland. Other antimalarial 
drugs are identified by The Ohio State University (OSU) code numbers (18). New OSU 
compounds used were, OSU1, OSU207 and OSU255 with molecular weights of 387.3, 427.4, 
and 444.35, respectively. 
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 Nucleotide sequence accession numbers. The sequences reported here have been 
deposited in GenBank under accession numbers AY061860 to AY061873. 
 
RESULTS  
 Antimicrobial activity of Mef and OSU compounds. To test if Mef and OSU 
compounds specifically target the F0F1 ATPase of S. pneumoniae, their MICs against Opt
R and 
QinR strains were determined (Table 1). The strains used were R6 mutants with defined point 
mutations in atpC, selected either via Opt resistance (strains MJ11 and MJ2) (6), or Qin 
resistance (strains MJQ3 and MJQ4) (24). Susceptible strains used as controls were R6, and 
the ATCC strains 6303 and 49619. When these strains are considered, Mef and OSU 
compounds were 2.4 to 10-fold more active than Opt and 40 to >300-fold more active than 
Qin in inhibiting the growth of S. pneumoniae. When the MICs against R6 were compared to 
those against their MJ2, MJ11, MJQ3, and MJQ4 mutants, significant increases (variations  
2-fold the MIC) in resistance to Mef, OSU 1, and OSU 8 were observed for strains MJQ3 and 
MJQ4, and MJQ3 also showed an increase in resistance higher than 15-fold to OSU 199 and 
OSU 207. However, strain MJ2 only showed increased resistance to Mef, and OSU207, 
whereas strain MJ11 did not showed any differences for the compounds assayed. None of the 
mutant strains had increased resistance to OSU compounds 95, 99, 255, and 259 (Table 1). 
Taking together, these results suggest that the c subunit of the F0 complex of the F0F1 ATPase 
is the target for Mef and OSU compounds 1, 8, 199 and 207, and that each mutant displays a 
characteristic pattern of inhibition with the various compounds. 
 Characterization of MefR S. pneumoniae strains. MefR strains were obtained by plating 
2 × 1010 R6 cells in 0.3 g/ml Mef (2-fold the MIC). One isolate, designated as MJM1, was 
obtained. The atpC and atpA genes of this strain were PCR amplified with oligonucleotides 
atporf1 and atpB56, and sequenced. A single mutation was observed in atpA, i.e., an TTT 
codon in strain R6 was changed to TCT that would produce a F209S change in the predicted 
amino acid sequence of the a subunit of the MJM1 F0F1 ATPase (not shown). To provide 
genetic evidence that this change was indeed involved in Mef resistance, the PCR product 
obtained from strain MJM1 DNA carrying atpCA was used to transform competent R6 cells, 
 7 
and the same PCR product, but from R6 DNA, was used as a control. As expected, the PCR 
product from MJM1 transformed R6 with high efficiency (higher than 105 transformants/ml) 
to Mef resistance. However, the R6 PCR product was also able to transform, although with 
much lower efficiency (103 transformants/ml). Two colonies, selected from the transformation 
with the MJM1 PCR product, showed to carry the F209S amino acid change in the a subunit, 
indicating that this mutation was indeed involved in Mef resistance. One of these 
transformants was named MJM11 (Table 2) and used for further studies. From the 
transformation experiment with the R6 PCR product, several colonies were selected and the 
sequences of their aptCA genes determined. These strains carried point mutations either in the 
atpC gene (MJM5, 7, 8, 9, 10, 13, 14, and 15) or in atpA (MJM3, 6, 11, 21, and 22) (Table 2). 
Genetic evidence showing that the mutations carried by these strains were indeed involved in 
resistance was obtained by genetic transformation. PCR products carrying those mutations 
were able to transform the MefS strain R6 with high efficiency (higher that 105 
transformants/ml) to MefR. The susceptibilities of these strains to Mef and OSU compounds 
was analyzed, with exception of MJM10 and 14 that had amino acid substitutions identical to 
MJQ3 and Q4, respectively. All mutant strains selected for resistance to Mef showed 
significant increases in their CMIs to this compound (from 4 to 64-fold) and to OSU199 (4 to 
32-fold). All but MJM7 had increased resistance to optochin (4 to 32-fold) and OSU1 (4 to 
64-fold), and all but MJM6, MJM8 and MJM11 to quinine (4 to 8-fold) (Table 1).  
 The appearance of MefR colonies in the transformation with the 1,277-bp PCR product 
carrying the R6 atpCA genes might be attributed to the error rate of the polymerase. This rate 
is of 1 error/ 10 kbp, and then an error would be expected for 10 molecules of 1-kb. From our 
results, about 1 % (10-2) of the putative nt changes would result in a residue change conferring 
MefR. Since 9 x 106 cells were used in the transformation experiments, the expected number 
of clones with MefR mutations would be of 9 x 103, a figure consistent with the results 
obtained. Furthermore, when a 1,158-bp fragment of an unrelated gene (parE, coding for the 
ParE subunit of DNA topoisomerasa IV), was amplified and used in transformation 
experiments, the frequency of MefR colonies was equivalent to that obtained in the control 
with no DNA (no colonies appeared in 0.1 ml of the transformation mixture, that gives a 
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frequency lower that 10 transformants/ml). In addition, similar number (5 x 102 
transformants/ml) of MefR colonies were observed when a proofreading enzyme was used in 
the amplification of the atpCA genes, and no MefR colonies appeared when the parE was 
amplified with this enzyme. 
 
 Characteristics of the mutations affecting the c and a subunits of the F0F1 ATPase of 
S. pneumoniae. Predictions of the secondary structure of subunits c and a subunits were made 
by the PHD method (29-31) using an electronic mail server (http://www.embl-heidelberg.de). 
Those calculations predicted 2 transmembrane -helices for the c subunits and 6 for the a 
subunits of S. pneumoniae and E.coli (Fig. 2). Among the 13 MefR strains obtained by 
selection with Mef (named MJMX, M for Mef, Table 2), 8 carried mutations in atpC and 5 in 
atpA. All amino acid residues that changed in the MefR stains were located in a predicted 
transmembrane -helix (Table 2, Fig. 2). In the c subunit, 5 strains showed changes in helix-1 
and 3 in helix 2, while the changes in the a subunit were at residues located in helix 5 (one 
strain) and in helix 4 (4 strains).   
 Inhibition of the F0F1 ATPase by Mef and OSU compounds. Biochemical evidence for 
the targeting of the F0F1 ATPase by Mef and related compounds was obtained by testing the 
inhibition of the ATPase activity of membranes obtained from R6 and the mutant strains. All 
compounds inhibited the R6 ATPase activity, including those compounds (OSU95, 99, 255, 
and 259) that inhibited the growth of both sensitive and resistant strains (Table 1). The 
inhibition of the strains by Mef, OSU1, OSU8, OSU 199, and OSU207 of the ATPase activity 
(IC50 values) showed a good correlation with their MICs (Fig. 1), indicating that the primary 
target for these compounds in the cell is the membrane ATPase. A good correlation was also 
obtained when the IC50 values of the different compounds were plotted against MICs for strain 
MJQ4, a strain that showed an intermediate sensitivity to most of the compounds (Fig. 1), 
indicating that all compounds share the same target in the cell.    
 
DISCUSSION 
 Combined genetic and biochemical studies support a hairpin-like structure for the c 
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subunit with two -helices that transverse the membrane in an antiparallel fashion, separated 
by a conserved polar loop region that forms the F1 binding region (14). The Mef
R 
pneumococcal strains had point mutations that change amino acid residues located in one of 
the two transmembrane -helices of the c subunit at positions close to the two acidic residues 
E19 and E52 (Table 2, Fig. 2). Although previously characterized OptR strains, selected via 
optochin resistance (strains MJ2 and MJ11) had mutations in helix-1 (6) and strains selected 
via quinine resistance (MJQ3 and MJQ4) had mutations in helix-2 (24), the strains selected 
via Mef resistance had mutations in either helix-1 or -2 (Table 2, Fig. 2). However, 
independently of the compound used for mutant selection, cross-resistance to those three 
antimalarial agents was observed (Table 1, Figs 1-2), suggesting that these chemically similar 
drugs interact with the c subunit in the same region of the protein, the ion-binding pocket. In 
the E. coli pocket, the D61 side chain is positioned within a four-helix bundle formed by the 
front and back faces of two adjacent monomers, D61 of helix-2 of one monomer packing in 
close proximity to residues A24 and I28 of helix-1, and A62 of helix-2 of the neighbouring 
monomer (5, 13) in a cavity created by the absence of side-chains at G23, G27, and G58 (8). 
Interestingly, two of the S. pneumoniae resistant strains (MJ11, MJM5) had amino acid 
changes at positions equivalent to G23 and G58 of E. coli (Table 2, Fig. 2), and changes G to 
A are found in strains MJQ4 and MJM15. All these results suggest a structure for the 
oligomeric subunit c ring of S. pneumoniae compatible with that of E. coli. However, whereas 
the E. coli c subunit has only one carboxyl group (D61 of  helix-2), the S. pneumoniae c 
subunit has two groups, located in a centered position in one of each alpha helices (E19 and 
E52, equivalent to I28 and D61 of E. coli), suggesting that both carboxylic groups would be 
involved in proton translocation. In agreement with this hypothesis, functional ATPases from 
E. coli mutants in which the essential carboxyl group of the c subunit has been switched to 
position 24 of helix-1 (equivalent to V15 of S. pneumoniae) (22) or in which a second 
carboxyl group has been introduced at position 28 (equivalent to E19 of S. pneumoniae) (12) 
have been described. 
 Additionally to mutations in the c subunit, five of the MefR strains carried mutations in 
two -helices of the a subunit: position L186 of the penultimate helix, and W206, F209 and 
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S214 of the ultimate helix (Fig. 2). These two helices are also present in the E. coli a subunit 
(Fig. 2). Studies of cysteine cross-linking (11) and nuclear magnetic resonance (28) have 
established that helix-2 of subunit c makes contact with the penultimate helix of subunit a 
(Fig. 2), residues S207, N214, A217, I221, I223, L224 and I225 lying in one face of the 
transmembrane helix, which then interact with helix-2 of subunit c. This proximity of the 
helices supports the possibility of an interaction between R210 of the a subunit and D61 of the 
c subunit during proton translocation. The location of the L186P change in the MJM21 S. 
pneumoniae strain is in accordance to this model of the F0 complex of E. coli.  
 Four residue changes present in the S. pneumoniae resistant strains are located in the last 
helix of subunit a (Fig. 2), suggesting an interaction between this helix of the a subunit and 
any of the helices of the c subunit. Although no cross-linking formation has been observed 
between helix-1 of the E. coli subunit c and the last helix of subunit a (11), a mutant strain 
with a H245D substitution shows a 45% reduction of normal proton translocation (3) and 
structural studies have defined one hydrophilic pathway between R210 of the E. coli a subunit 
and the periplasmic surface including residues N238, H245, and Q252 of the last helix of this 
protein (11). 
 The location and nature of the amino acid changes found in the c subunit of the R6 
descendants reported here are in accordance with those observed in pneumococcal optochin-
resistant clinical isolates, which showed G20S, M23I, A49T, V48F, and F50L changes (6, 27). 
In addition, a change in the a subunit (W206S), that corresponds to that found in strain MJM3, 
has also been recently reported in a clinical isolate of S. pneumoniae (27).  
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Figure 1. Correlations between inhibition of the ATPase activity and inhibition of growth by 
Mef and OSU compounds of membranes the strains indicated (A) and of membranes of MJQ4 
with the different compounds.  
Figure 2. Comparisons of the amino acid sequences and secondary structures of the c and a 
subunits of S. pneumoniae (SPN) and E. coli (ECO). Predicted -helices are showed above the 
SPN sequence and below the ECO sequence: gray and solid bars indicate, respectively, 
predictions made by the PHD method and according to Miller et al. (for the c subunit) (22) or 
to Valiyaveetil and Fillingame (35) (for the a subunit). Residues mutated in the pneumococcal 
resistant strains are showed in boldface and underlined. Residues of the ECO a subunit 
involved in interactions with the c subunit (11) are shown boldfaced and doubly underlined. 
Residues involved in proton translocation in E. coli and the equivalent S. pneumoniae residues 




TABLE 1. Susceptibilities of S. pneumoniae strains to amino alcohol antimalarials   
 
Strains 
MIC (g/ml) a of 
           
 Opt Qin Mef  OSU1 OSU8 OSU95 OSU99 OSU199 OSU207 OSU255 OSU259 
 ATCC 6303    0.75   25 0.15  0.15   0.15     0.15     0.15    0.31    0.15    0.07     0.15 
 ATCC 49619     1.5   50 0.15  0.15   0.31     0.62     0.62    0.62    0.15    0.15     0.15 
 R6     1.5   50 0.15  0.15   0.31     0.15     0.62    0.31    0.15    0.62     1.25 
 MJ11  24   72 0.15  0.15   0.31     0.15     0.62    0.15    0.07    0.62     1.25 
 MJ2  24 230 0.62  0.31   0.62     0.31     0.31    0.15    0.62    1.25     1.25 
 MJQ3    3 144 5  2.5   5      0.31     0.31    5    5    1.25     1.25 
 MJQ4  18 180 2.5  1.25   2.5     0.31     0.31    0.31    0.62    1.25     1.25 
 MJM3    6 200 2.5  5       5    
 MJM5  48 200 5  5       5    
 MJM6  12 100 2.5  0.62       1.25    
 MJM7    3 200 1.25  0.31       0.62    
 MJM8    6 100 5  2.5       2.5    
 MJM9  12 200 0.62  1.25       1.25    
 MJM11  12 100 2.5  1.25       2.5    
 MJM13  24 400 10 10     10    
 MJM15  12 200 5  2.5       2.5    
 MJM21    6 200 2.5  2.5       2.5    
 MJM22  24 200 2.5 2.5       5    
 
a Opt, optochin; Qin, quinine, Mef, mefloquine; , not determined. 
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TABLE 2. Mutational substitutions of the c and a subunits of S. pneumoniae strains resistant 
to amino alcohol antimalarial agents   
 
Strain 
Amino acid change (codon change)a 
c subunit  a subunit 
 -helix 1 -helix 2  -helix 5 -helix 6 
R6 13MGVSVGEGLLMN24 44MFLGVAFIEGTFFV57  178GEVMTSLLLL187 205AWTAFSVFIS214 
MJ11  A49T (GCCACC)    
MJ2  V48L (GTTCTT)    
MJQ3 M23I (ATGATA)     
MJQ4 G20A (GGTGCT)     
MJM3     W206G (TGGGGG) 
MJM5 G14S (GGCAGC)     
MJM6     S214P (TCCCCC) 
MJM7  V57L (GTACTA)    
MJM8 M13T (ATGACG)     
MJM9  M44V (ATGGTG)    
MJM10 M23I (ATGATT)     
MJM11     F209S (TTTTCT) 
MJM13 N24Y (AATTAT)     
MJM14 G20A (GGTGCT)     
MJM15  G47A (GGTGCT)    
MJM21    L186P (CTTCCT)  
MJM22     W206C (TGGTGT) 
 
a  The amino acid positions indicated refer to the S. pneumoniae R6 coordinates (accession number 
Z26851, see ref. 6). Residues that changed in the mutant strains indicated are showed in boldface. The 
E residues possibly involved in proton translocation are showed underlined in the -helices of the c 
subunit.  
 
